Early trials show reduction in liver fibrosis

Early trials show reduction in liver fibrosis

The American Association for the Study of Liver Diseases published findings that the ASK1 Inhibitor Selonsertib reduced liver fibrosis in stage 2-3 liver fibrosis. In late 2016 Gilead announced that Selonsertib was being tested with “GS-9674″ an FXR agonist for PBC.  Read more click here.

shares